期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 30, 期 5, 页码 543-554出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/13543784.2021.1901882
关键词
Epithelial ovarian cancer; PARP inhibitors; olaparib; niraparib; rucaparib; talazoparib; veliparib
PARP inhibitors, targeting the loss of gene suppressor, block base-excision repair in cancer cells with BRCA mutations, leading to synthetic lethality and cell death, potentially playing a crucial role in personalized therapeutic programs for EOC treatment.
Introduction Poly (ADP-ribose) polymerase (PARP) inhibitors are being developed in maintenance and recurrence treatment settings of epithelial ovarian cancers (EOCs) with BRCA 1-2 gene mutation. PARP inhibitors are the first example of drugs targeting the loss of a gene suppressor: they block base-excision repair in the cancer cells, which have lost homologous recombination due to BRCA-mutation, resulting in loss of DNA repair and cell death, also known as synthetic lethality. Areas covered This article provides an overview of PARP inhibitors in OC treatment and also an extensive section on the combined strategies of PARP inhibitors, including approved as well as currently investigated drugs. It also offers a section on the use of predictive biomarkers for PARP inhibitors treatment. Ongoing trials, including novel combinations, are discussed. Expert opinion In recent years, there is increasing evidence that PARP inhibitor therapy can have life-long percussion in the treatment of EOC, even if some questions have to be solved yet, such as its use in combination therapy, the possibility to retreat with a PARP inhibitor, and finally how to overcome a resistance mechanism to this therapy. In this way, PARP inhibitors can obtain an important role in making a personalized therapeutic program in the case of first-line, neoadjuvant, platinum-sensitive, and resistant high-grade serous OC treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据